Skip to contentpdufa.bio

vidofludimus calcium (IMU-838)

Page updated ·next FDA decision on the calendar ·Data as of Nov 17, 2026 9:34 PM ET

vidofludimus calcium (IMU-838) is an Immunic, Inc. program in relapsing multiple sclerosis. Its next catalyst is a Readout in Dec 2026. Every date links its source.

IMUX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: relapsing multiple sclerosis. Sponsor: Immunic, Inc. (IMUX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 2026IMUX

Questions

When is vidofludimus calcium (IMU-838)'s next FDA decision or readout?

The next tracked catalyst for vidofludimus calcium (IMU-838) is a Readout in Dec 2026.

What happened at vidofludimus calcium (IMU-838)'s most recent FDA decision?

No FDA decision for vidofludimus calcium (IMU-838) is in our archive yet.

What is vidofludimus calcium (IMU-838) used for?

In our records vidofludimus calcium (IMU-838) is under review or in development for relapsing multiple sclerosis.

Who makes vidofludimus calcium (IMU-838)?

Immunic, Inc. (IMUX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.